validated VHH technology to develop treatments for viral infections that may pose a significant global threat.

ExeVir Bio develops a rapid response platform for antivirals. This platform technology enables an agile response to new health threats thanks to its short throughput time to generate drug candidates. The resulting protein-based therapeutics are sufficiently stable and easy to produce at a reasonable cost to enable true global access.

ExeVir Bio was founded in 2020 and is headquartered in Zwijnaarde, Belgium.